Advanced Oncotherapy (AVO)

Sector:

Health Care

 1.93p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 25.00
  • 52 Week Low: 1.75
  • Currency: UK Pounds
  • Shares Issued: 542.57m
  • Volume: 0
  • Market Cap: £10.44m

Advanced Oncotherapy adds Jonathan Farr as senior VP

By Josh White

Date: Wednesday 14 Jun 2017

LONDON (ShareCast) - (ShareCast News) - Next-generation proton therapy systems developer Advanced Oncotherapy announced the appointment of Jonathan Farr as senior vice-president of medical physics with immediate effect on Wednesday.
The AIM-traded firm said Dr Farr would not be taking a board position.

It said Dr Farr is a medical physicist working in the treatment of cancer, specialising in proton therapy.

His experience in developing "high definition and accurate" proton treatment systems, their clinical use and characterisation, advanced radiotherapy treatment planning and novel image guidance and patient positioning, closely matched the company's goal of commercialising the next generation of proton therapy systems, the board claimed.

He would be based in Geneva, and would be leading the clinical application of and further advances in LIGHT's patient treatment systems.

"Jonathan provides us with extensive expertise in proton therapy patient treatment," said CEO Nicolas Serandour.

"He has a keen interest in innovation and is ideally suited to maximise the clinical benefits from LIGHT's next-generation technology.

"His appointment, alongside Ed Lee's, which was announced on 13 June, is a further endorsement of the ground-breaking work we are doing at Advanced Oncotherapy."

Commenting on his appointment, Dr Farr said the "next generation" of proton therapy, embodied in AVO's technologically system, would make proton therapy more effective and accessible.

"My new role with AVO is translating the complex proton therapy system into powerful and efficient application at the clinical level.

"Together with my experienced colleagues, we are working on optimisations to leverage the LIGHT system from clinical, patient access and shareholder points of view," Dr Farr said.

"My international experience, honed in Europe and the United States, provides me with the unique ability to do this."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

AVO Market Data

Currency UK Pounds
Share Price 1.93p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 25.00
52 Week Low 1.75
Volume 0
Shares Issued 542.57m
Market Cap £10.44m

AVO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
74.4% below the market average74.4% below the market average74.4% below the market average74.4% below the market average74.4% below the market average
40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average
Income Not Available
Growth Not Available

AVO Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

AVO Key Personnel

CEO Nicolas Serandour

Top of Page